Pretreatment neutrophil-to-lymphocyte ratio as an important prognostic marker in stage III locally advanced non-small cell lung cancer: confirmatory results from the PROCLAIM phase III clinical trial.

J Thorac Dis · 2021 · PMC8575807 · PMID 34795912

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a significant trendno p-value reported

Increasing baseline neutrophil counts showed a significant trend for worse OS, before and after adjusting for demographic characteristics i.e., age, BMI, cancer type, gender ( P Trend <0.0001); however, no such association was noted for PFS.

also in 9,775 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.